Fresenius Kabi has introduced its generic Alkeran (melphalan hydrochloride for injection). The drug is indicated as a palliative treatment for patients with multiple myeloma for whom oral therapy is not appropriate.

Fresenius Kabi’s generic Alkeran is available as a two-vial kit with one single-dose vial of the drug and one vial of sterile diluent.

This is the third launch in recent weeks from the Lake Zurich, Ill.-based company, which earlier in April launched its generic Cubicin and an alternative to Aloxi.